Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
In addition to serving as an editor at publications like Allure, Good Housekeeping, xoVain, and NewBeauty, Marci's writing has appeared in Glamour, InStyle, Refinery29, Martha Stewart, Byrdie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback